סימבאסטאטין - Simvastatin

סימבאסטאטין - Simvastatin
התוויות	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvastatin-teva is indicated to: Reduce the risk of total mortality by reducing coronary death ; Reduce the risk of non-fatal myocardial infarction ; Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvastatin-teva is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvastatin-teva therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvastatin-teva is indicated for the treatment of patients with hypertriglyceridemia ( Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia (Fredrickson type III hyperlipidemia): Simvastatin-teva is also indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia)

לערכים נוספים הקשורים לנושא זה, ראו את דף הפירושים – סטטין

סימבאסטאטין - Simvastatin
שמות מסחריים	®SIMOVIL® ; SIMVASTATIN® ; SIMVAXON


קבוצה פרמקולוגית (ATC)	"HMG COA REDUCTASE INHIBITORS"
שם גנרי	"סימבאסטאטין" (קישור לדף התרופה במאגר משרד הבריאות)
סל הבריאות	כלול
מסגרת הכללה בסל	תרופה מוגבלת לרישום ע"י רופא מומחה או הגבלה אחרת.
התוויות	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvastatin-teva is indicated to: Reduce the risk of total mortality by reducing coronary death ; Reduce the risk of non-fatal myocardial infarction ; Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvastatin-teva is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvastatin-teva therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvastatin-teva is indicated for the treatment of patients with hypertriglyceridemia ( Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia (Fredrickson type III hyperlipidemia): Simvastatin-teva is also indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia)
קיים גם בתכשירים	®INEGY